|
Gene: LILRB1 |
Gene summary for LILRB1 |
Gene summary. |
Gene information | Species | Human | Gene symbol | LILRB1 | Gene ID | 10859 |
Gene name | leukocyte immunoglobulin like receptor B1 | |
Gene Alias | CD85J | |
Cytomap | 19q13.42 | |
Gene Type | protein-coding | GO ID | GO:0001501 | UniProtAcc | A0A087WSV6 |
Top |
Malignant transformation analysis |
Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
Malignant transformation involving gene list. |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
10859 | LILRB1 | HCC1 | Human | Liver | HCC | 1.17e-09 | 8.65e-01 | 0.5336 |
10859 | LILRB1 | HCC2 | Human | Liver | HCC | 6.10e-25 | 1.82e+00 | 0.5341 |
10859 | LILRB1 | HCC5 | Human | Liver | HCC | 2.21e-11 | 1.57e+00 | 0.4932 |
10859 | LILRB1 | Pt13.c | Human | Liver | HCC | 2.85e-03 | 2.59e-01 | 0.0076 |
10859 | LILRB1 | Pt14.d | Human | Liver | HCC | 4.57e-04 | 1.62e-01 | 0.0143 |
Page: 1 |
Transcriptomic changes along malignancy continuum. |
Tissue | Expression Dynamics | Abbreviation |
Liver | HCC: Hepatocellular carcinoma | |
NAFLD: Non-alcoholic fatty liver disease |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
Figure of enriched GO biological processes. |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | |
Colorectum | SER | |
Colorectum | MSS | |
Colorectum | MSI-H | |
Colorectum | FAP |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
Enriched GO biological processes. |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:000961511 | Liver | HCC | response to virus | 210/7958 | 367/18723 | 7.32e-09 | 1.86e-07 | 210 |
GO:00516071 | Liver | HCC | defense response to virus | 151/7958 | 265/18723 | 1.27e-06 | 1.85e-05 | 151 |
GO:01405461 | Liver | HCC | defense response to symbiont | 151/7958 | 265/18723 | 1.27e-06 | 1.85e-05 | 151 |
GO:0045786 | Liver | HCC | negative regulation of cell cycle | 204/7958 | 385/18723 | 1.84e-05 | 1.99e-04 | 204 |
GO:0032479 | Liver | HCC | regulation of type I interferon production | 60/7958 | 95/18723 | 3.84e-05 | 3.80e-04 | 60 |
GO:0032606 | Liver | HCC | type I interferon production | 60/7958 | 95/18723 | 3.84e-05 | 3.80e-04 | 60 |
GO:003009922 | Liver | HCC | myeloid cell differentiation | 200/7958 | 381/18723 | 4.64e-05 | 4.49e-04 | 200 |
GO:004311221 | Liver | HCC | receptor metabolic process | 96/7958 | 166/18723 | 4.69e-05 | 4.50e-04 | 96 |
GO:000689821 | Liver | HCC | receptor-mediated endocytosis | 134/7958 | 244/18723 | 5.73e-05 | 5.31e-04 | 134 |
GO:00028321 | Liver | HCC | negative regulation of response to biotic stimulus | 66/7958 | 108/18723 | 7.24e-05 | 6.50e-04 | 66 |
GO:00028312 | Liver | HCC | regulation of response to biotic stimulus | 173/7958 | 327/18723 | 8.55e-05 | 7.48e-04 | 173 |
GO:003010021 | Liver | HCC | regulation of endocytosis | 117/7958 | 211/18723 | 9.56e-05 | 8.32e-04 | 117 |
GO:003249611 | Liver | HCC | response to lipopolysaccharide | 174/7958 | 343/18723 | 1.19e-03 | 6.62e-03 | 174 |
GO:00712166 | Liver | HCC | cellular response to biotic stimulus | 128/7958 | 246/18723 | 1.53e-03 | 8.10e-03 | 128 |
GO:00712226 | Liver | HCC | cellular response to lipopolysaccharide | 110/7958 | 209/18723 | 1.92e-03 | 9.77e-03 | 110 |
GO:004578512 | Liver | HCC | positive regulation of cell adhesion | 215/7958 | 437/18723 | 2.53e-03 | 1.22e-02 | 215 |
GO:000223711 | Liver | HCC | response to molecule of bacterial origin | 181/7958 | 363/18723 | 2.58e-03 | 1.24e-02 | 181 |
GO:00450881 | Liver | HCC | regulation of innate immune response | 113/7958 | 218/18723 | 3.27e-03 | 1.50e-02 | 113 |
GO:0050688 | Liver | HCC | regulation of defense response to virus | 41/7958 | 69/18723 | 3.38e-03 | 1.54e-02 | 41 |
GO:00458241 | Liver | HCC | negative regulation of innate immune response | 42/7958 | 71/18723 | 3.41e-03 | 1.55e-02 | 42 |
Page: 1 2 |
Enriched KEGG pathways. |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
HLA-F | LILRB1 | HLA-F_LILRB1 | MHC-I | Breast | DCIS |
HLA-F | LILRB1 | HLA-F_LILRB1 | MHC-I | Breast | Healthy |
HLA-F | LILRB1 | HLA-F_LILRB1 | MHC-I | Cervix | CC |
HLA-F | LILRB1 | HLA-F_LILRB1 | MHC-I | Cervix | Precancer |
HLA-F | LILRB1 | HLA-F_LILRB1 | MHC-I | CRC | AD |
HLA-F | LILRB1 | HLA-F_LILRB1 | MHC-I | CRC | SER |
HLA-F | LILRB1 | HLA-F_LILRB1 | MHC-I | Endometrium | ADJ |
HLA-F | LILRB1 | HLA-F_LILRB1 | MHC-I | Endometrium | EEC |
HLA-F | LILRB1 | HLA-F_LILRB1 | MHC-I | Endometrium | Healthy |
HLA-F | LILRB1 | HLA-F_LILRB1 | MHC-I | HNSCC | OSCC |
HLA-F | LILRB1 | HLA-F_LILRB1 | MHC-I | Liver | HCC |
HLA-F | LILRB1 | HLA-F_LILRB1 | MHC-I | Liver | Healthy |
HLA-F | LILRB1 | HLA-F_LILRB1 | MHC-I | Liver | Precancer |
HLA-F | LILRB1 | HLA-F_LILRB1 | MHC-I | Skin | cSCC |
HLA-F | LILRB1 | HLA-F_LILRB1 | MHC-I | THCA | ADJ |
HLA-F | LILRB1 | HLA-F_LILRB1 | MHC-I | THCA | Cancer |
HLA-F | LILRB1 | HLA-F_LILRB1 | MHC-I | THCA | Precancer |
HLA-F | LILRB1 | HLA-F_LILRB1 | MHC-I | THCA | PTC |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
Annotation of somatic variants for genes involved in malignant transformation |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
LILRB1 | SNV | Missense_Mutation | novel | c.1900T>C | p.Ser634Pro | p.S634P | protein_coding | tolerated(0.12) | benign(0.024) | TCGA-A5-A7WJ-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
LILRB1 | SNV | Missense_Mutation | rs763484018 | c.1517N>T | p.Ala506Val | p.A506V | protein_coding | tolerated(0.06) | benign(0.068) | TCGA-AJ-A2QO-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
LILRB1 | SNV | Missense_Mutation | novel | c.1817C>T | p.Ala606Val | p.A606V | protein_coding | deleterious(0.02) | benign(0.192) | TCGA-AJ-A3BH-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | Unknown | I/II | Unknown | Unknown | SD | |
LILRB1 | SNV | Missense_Mutation | novel | c.1112C>T | p.Ser371Leu | p.S371L | protein_coding | tolerated(0.07) | probably_damaging(0.945) | TCGA-AJ-A3EK-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Chemotherapy | carboplatin | CR | |
LILRB1 | SNV | Missense_Mutation | novel | c.1547N>T | p.Arg516Ile | p.R516I | protein_coding | deleterious(0.02) | possibly_damaging(0.888) | TCGA-AJ-A3OJ-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Chemotherapy | carboplatin | CR | |
LILRB1 | SNV | Missense_Mutation | c.1597N>A | p.Leu533Ile | p.L533I | protein_coding | tolerated(0.06) | possibly_damaging(0.784) | TCGA-AP-A051-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | ||
LILRB1 | SNV | Missense_Mutation | novel | c.1366C>A | p.Leu456Met | p.L456M | protein_coding | deleterious(0.01) | probably_damaging(0.996) | TCGA-AP-A0LM-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | cisplatin | SD | |
LILRB1 | SNV | Missense_Mutation | novel | c.382N>C | p.Ser128Pro | p.S128P | protein_coding | deleterious(0) | probably_damaging(0.951) | TCGA-AP-A1DV-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
LILRB1 | SNV | Missense_Mutation | novel | c.761N>T | p.Arg254Ile | p.R254I | protein_coding | deleterious(0) | benign(0.444) | TCGA-AP-A1DV-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
LILRB1 | SNV | Missense_Mutation | rs376436279 | c.1484N>T | p.Ser495Leu | p.S495L | protein_coding | tolerated(0.14) | benign(0.019) | TCGA-AP-A1DV-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
Page: 1 2 3 4 5 6 7 8 9 10 11 |
Top |
Related drugs of malignant transformation related genes |
Identification of chemicals and drugs interact with genes involved in malignant transfromation |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |